Suppr超能文献

卡维地洛治疗普萘洛尔治疗反应不佳的肝硬化患者原发性预防静脉曲张出血。

Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.

机构信息

Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, , Vienna, Austria.

出版信息

Gut. 2013 Nov;62(11):1634-41. doi: 10.1136/gutjnl-2012-304038. Epub 2012 Dec 18.

Abstract

OBJECTIVE

Non-selective β-blockers or endoscopic band ligation (EBL) are recommended for primary prophylaxis of variceal bleeding in patients with oesophageal varices. Additional α-adrenergic blockade (as by carvedilol) may increase the number of patients with haemodynamic response (reduction in hepatic venous pressure gradient (HVPG) of ≥ 20% or to values <12 mm Hg).

DESIGN

Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included. HVPG responders were kept on propranolol (PROP group), while non-responders were placed on carvedilol (6.25-50 mg/day). Carvedilol responders continued treatment (CARV group), while non-responders to carvedilol underwent EBL. The primary aim was to assess haemodynamic response rates to carvedilol in propranolol non-responders.

RESULTS

36% (37/104) of patients showed a HVPG response to propranolol. Among the propranolol non-responders 56% (38/67) eventually achieved a haemodynamic response with carvedilol, while 44% (29/67) patients were finally treated with EBL. The decrease in HVPG was significantly greater with carvedilol (median 12.5 mg/day) than with propranolol (median 100 mg/day): -19 ± 10% versus -12 ± 11% (p<0.001). During a 2 year follow-up bleeding rates for PROP were 11% versus CARV 5% versus EBL 25% (p=0.0429). Fewer episodes of hepatic decompensation (PROP 38%/CARV 26% vs EBL 55%; p=0.0789) and significantly lower mortality (PROP 14%/CARV 11% vs EBL 31%; p=0.0455) were observed in haemodynamic responders compared to the EBL group.

CONCLUSIONS

Carvedilol leads to a significantly greater decrease in HVPG than propranolol. Using carvedilol for primary prophylaxis a substantial proportion of non-responders to propranolol can achieve a haemodynamic response, which is associated with improved outcome with regard to prevention of variceal bleeding, hepatic decompensation and death.

摘要

目的

非选择性β受体阻滞剂或内镜套扎(EBL)被推荐用于食管静脉曲张患者的静脉曲张出血的一级预防。额外的α肾上腺素能阻断(如卡维地洛)可能会增加血液动力学反应(肝静脉压力梯度(HVPG)降低≥20%或至<12mmHg)的患者数量。

设计

纳入接受普萘洛尔治疗(80-160mg/天)前和治疗下测量 HVPG 的食管静脉曲张患者。HVPG 反应者继续服用普萘洛尔(PROP 组),而无反应者服用卡维地洛(6.25-50mg/天)。卡维地洛反应者继续治疗(CARV 组),而卡维地洛无反应者接受 EBL。主要目的是评估普萘洛尔无反应者对卡维地洛的血液动力学反应率。

结果

36%(104 例中的 37 例)的患者对普萘洛尔有 HVPG 反应。在普萘洛尔无反应者中,56%(67 例中的 38 例)最终通过卡维地洛实现血液动力学反应,而 44%(67 例中的 29 例)患者最终接受 EBL 治疗。卡维地洛的 HVPG 降低幅度明显大于普萘洛尔(中位数 12.5mg/天):-19±10%与-12±11%(p<0.001)。在 2 年的随访期间,PROP 的出血率为 11%,CARV 为 5%,EBL 为 25%(p=0.0429)。肝功能失代偿(PROP 38%/CARV 26%vs EBL 55%;p=0.0789)和死亡率(PROP 14%/CARV 11%vs EBL 31%;p=0.0455)明显降低。

结论

卡维地洛导致 HVPG 的降低明显大于普萘洛尔。使用卡维地洛进行一级预防,普萘洛尔无反应者中有相当一部分可以实现血液动力学反应,这与预防静脉曲张出血、肝功能失代偿和死亡方面的改善结果相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验